BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Geier A, Boursier J. Non-invasive diagnosis of patients with 'at-risk' NAFLD : only fibrosis counts? Gut 2020;69:1164-5. [PMID: 32220903 DOI: 10.1136/gutjnl-2020-320785] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Dietrich CG, Rau M, Geier A. Screening for nonalcoholic fatty liver disease-when, who and how? World J Gastroenterol 2021; 27(35): 5803-5821 [PMID: 34629804 DOI: 10.3748/wjg.v27.i35.5803] [Reference Citation Analysis]
2 Rau M, Geier A. An update on drug development for the treatment of nonalcoholic fatty liver disease - from ongoing clinical trials to future therapy.Expert Rev Clin Pharmacol. 2021;14:333-340. [PMID: 33535836 DOI: 10.1080/17512433.2021.1884068] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
3 Boursier J, Hagström H, Ekstedt M, Moreau C, Bonacci M, Cure S, Ampuero J, Nasr P, Tallab L, Canivet CM, Kechagias S, Sánchez Y, Dincuff E, Lucena A, Roux M, Riou J, Trylesinski A, Romero-gomez M. Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2021.12.031] [Reference Citation Analysis]
4 Geier A, Tiniakos D, Denk H, Trauner M. From the origin of NASH to the future of metabolic fatty liver disease. Gut 2021:gutjnl-2020-323202. [PMID: 33632710 DOI: 10.1136/gutjnl-2020-323202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Michel M, Schattenberg JM. [Liver-specific diagnostic for non-alcoholic fatty liver disease (NAFLD) - time to replace liver biopsy?]. Z Gastroenterol 2020;58:1233-40. [PMID: 33291177 DOI: 10.1055/a-1291-8483] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]